A study of CCND1 with epithelial ovarian cancer cell proliferation and apoptosis

J. Dai, R.-J. Wei, R. Li, J.-B. Feng, Y.-L. Yu, P.-S. Liu

Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, China. pl_sci@163.com

---

• Oncology

OBJECTIVE: Ovarian cancer is a gynecological malignancy with high mortality rates all over the world. Markers for diagnosis, prognosis and therapy are urgently required to improve the mortality rates. As a key proto-oncogene, CCND1 is known to be amplified in many different carcinomas, including breast cancer, esophageal cancer, bladder cancer, endometrial cancer and ovarian cancer, etc. CCND1 plays an important role in cancer development and progression. However, its function and mechanism have not been completely elucidated in ovarian cancer.

MATERIALS AND METHODS: In the present study, we use cisplatin in vitro to inhibit the cell proliferation and promote cell apoptosis in epithelial ovarian cancer cell line SKOV-3. CCND1 expression, cell proliferation and cell cycle analysis were carried out by real-time PCR, CCK-8 and flow cytometry respectively.

RESULTS: Our results demonstrated that cisplatin could inhibit the expression of CCND1 in human epithelial ovarian cancer cell line, which is related to the decreased cell proliferation and increased cell apoptosis.

CONCLUSIONS: This study demonstrated that CCND1 is a potential therapeutic target for epithelial ovarian cancer treatment.

Free PDF Download